
Company Legal Name
Latest Valuation
Founded Year
Headquarters
Tempus Labs, Inc. develops software platforms and genomic testing tools that enable personalized cancer treatment and clinical trial matching for patients and healthcare providers. Founded in 2015 and headquartered in Chicago, the company leverages artificial intelligence and machine learning to analyze clinical and molecular data, helping oncologists make more informed treatment decisions. Tempus has established partnerships with leading cancer centers and pharmaceutical companies, building one of the world's largest libraries of clinical and molecular data. The company continues to expand its precision medicine capabilities, focusing on advancing personalized healthcare through data-driven insights and improving patient outcomes across oncology.

Availability of information and platform features may vary by region and applicable requirements.
Eligibility and access may depend on user location, verification status, and applicable legal or regulatory requirements.
Additional platform details may be available after account creation, where applicable.
Identity, compliance, and other review steps may be required before access to certain materials or features.
Platform details, if applicable, should be reviewed in account materials before making any decision.
Any economic terms, if applicable, should be reviewed carefully in the relevant materials.

Private market interests may be illiquid, restricted, or difficult to transfer. Users should not assume that any secondary market will be available.
Valuations may reflect past financing rounds or other available information and may not represent a price at which any person can transact.
Company and sector risks may vary by business model, technology development, competition, regulation, and market conditions.
Operational, documentation, custody, or verification processes may involve limitations, delays, or dependencies.
Regulatory, tax, and legal requirements may change and may affect information availability, platform features, or user eligibility.


